Sagility has completed the acquisition of Chirok Health LLC for up to $32.35 million. The deal aims to strengthen Sagility’s capabilities in the provider segment through specialised clinical documentation and coding services.

Acquisition at a glance

The following table summarises the key details of the completed transaction:

Strategic intent and target profile

The acquisition is intended to enhance Sagility's capabilities in the healthcare services domain, specifically within the provider segment. By integrating Chirok Health, Sagility aims to add specialised Clinical Documentation Integrity (CDI), medical coding, and revenue optimisation capabilities to its existing portfolio. The transaction deepens Sagility's clinical domain expertise, expands its addressable market across providers and payers, and creates new opportunities to drive revenue growth through integrated clinical and revenue cycle solutions.

Chirok Health is a US-based company headquartered in Tennessee. It provides CDI, medical coding, Revenue Cycle Management (RCM), audit and quality assurance services, supported by its proprietary CHEMP workflow platform. The company supports healthcare organizations across fee-for-service and value-based care models.

Financial details of the transaction

The aggregate purchase consideration is capped at $32.35 million, structured as follows:

• An upfront payment of $20.0 million at closing, subject to customary adjustments.
• A contingent consideration of up to $12.35 million, payable upon the achievement of specified performance milestones.

The acquisition falls outside the scope of related party transactions, with no interest held by the promoter or promoter group in the entity being acquired. No governmental or regulatory approvals were required for the completion of this acquisition. Canaccord Genuity LLC served as the exclusive financial advisor to Chirok Health on the transaction.

Management commentary

Ramesh Gopalan, Managing Director and Group CEO of Sagility, stated that the acquisition is an important step in building a comprehensive provider-focused services platform. He noted that Chirok's leadership in clinical documentation improvement, medical coding, quality assurance programs, and revenue integrity complements existing capabilities. Together with the recent acquisition of CareSeed, this transaction enhances the ability to help healthcare organizations improve quality outcomes, optimize reimbursement, and advance value-based care initiatives.

Kanar Kokoy, Founder and CEO of Chirok Health, said joining Sagility represents an exciting next chapter. He emphasized that clients will continue to receive specialized expertise while gaining access to a broader set of capabilities to address evolving operational and financial challenges.

What the numbers show

The deal values Chirok Health at approximately 3.6 times its CY2025 turnover of $9.0 million. The target has shown revenue volatility over the last three years, recording turnovers of $12.7 million in CY2023, $8.2 million in CY2024, and recovering to $9.0 million in CY2025. The significant contingent portion of the deal ($12.35 million out of $32.35 million) suggests that Sagility is hedging against this historical volatility by tying a substantial part of the payment to future performance milestones.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0W2G01015/54137dff-8f37-4568-8d26-c7511e0e0a72.pdf

Sagility Limited has appointed Brian Clayton as its new Global General Counsel and Senior Management Personnel (SMP), effective October 2, 2026. The appointment follows the resignation of Daniel B. Bailey, who is leaving the role due to personal reasons.

The Board of Directors approved Clayton’s appointment based on the recommendation of the Nomination and Remuneration Committee. The change in senior managerial personnel was disclosed to stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Profile of incoming counsel

Brian Clayton brings over two decades of experience advising global organizations on legal, regulatory, compliance, privacy, and commercial matters. Prior to joining Sagility, he served as Associate General Counsel and Chief Privacy Officer at Omnicom Group. In that role, he led global privacy and compliance programs and advised executive leadership on enterprise legal matters.

Before his tenure at Omnicom, Clayton spent 20 years in senior legal leadership roles at Conduent, a multi-billion-dollar global business process outsourcing provider with significant healthcare operations. There, he partnered with business leaders across healthcare, technology, and business services sectors.

Clayton holds a Juris Doctor, cum laude, from New York Law School, where he served on Law Review, and a Bachelor of Science in Psychology from Nova Southeastern University. He also serves as an Adjunct Professor at Fordham University School of Law, teaching Privacy and Cybersecurity Law.

Transition details

Daniel B. Bailey tendered his resignation from the position of EVP, Global General Counsel, citing personal reasons. His cessation from the role is effective October 2, 2026. The company confirmed that Bailey’s departure is not related to any disagreement with the company on matters relating to operations, policies, or practices.

The disclosure notes that Clayton’s relationship with other directors is not applicable, indicating no immediate familial or business ties among the board members that require specific regulatory disclosure under the current guidelines.